MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

Rhea-AI Summary

Mangoceuticals (NASDAQ: MGRX), a company focused on men's health and wellness products, has announced a 1-for-15 reverse stock split effective October 16, 2024. This move is part of the company's plan to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse split will reduce MGRX's outstanding common stock from approximately 35.5 million shares to 2.4 million shares. The trading symbol will remain 'MGRX'. All outstanding options and securities will be adjusted accordingly, and no fractional shares will be issued. This decision follows stockholder approval at a Special Meeting on March 25, 2024.

Positive

• Potential to regain compliance with Nasdaq listing requirements
• Stockholder approval obtained for the reverse stock split

Negative

• Significant reduction in outstanding shares from 35.5 million to 2.4 million
• Potential dilution of shareholder value
• Indication of struggling stock price performance necessitating the split

Insights

Financial Analyst

The 1-for-15 reverse stock split announced by Mangoceuticals (MGRX) is a significant move aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This action will reduce the company's outstanding shares from approximately 35.5 million to 2.4 million, potentially increasing the stock price by a factor of 15.

Key points to consider:

• The move is primarily defensive, designed to maintain Nasdaq listing rather than reflecting improved business fundamentals.
• While the stock price may initially increase, the company's market cap remains unchanged, indicating no inherent value creation.
• Reverse splits can sometimes be viewed negatively by the market, as they're often associated with struggling companies.
• The effectiveness of this strategy depends on MGRX's ability to maintain the higher share price post-split, which will require improved financial performance or positive market sentiment.

Investors should closely monitor the company's future financial reports and market performance to assess the long-term impact of this corporate action.

Legal Expert

The reverse stock split by Mangoceuticals (MGRX) raises several legal and compliance considerations:

• The company has followed proper procedures by obtaining shareholder approval at a Special Meeting, demonstrating compliance with corporate governance requirements.
• The Board's discretion in determining the final ratio within approved parameters aligns with standard practices and likely complies with the company's bylaws.
• MGRX has filed the necessary documentation with the SEC, including updating their proxy statement and submitting a Form 8-K, which is important for maintaining transparency and regulatory compliance.
• The company's handling of fractional shares by rounding up to whole shares is a common and legally acceptable practice.

While the reverse split itself is legally sound, investors should be aware that it doesn't address underlying business challenges. The company will need to demonstrate improved financial performance to avoid future compliance issues with Nasdaq listing requirements.

DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-15 (the “Reverse Stock Split”). The Reverse Stock Split will become effective on October 16, 2024 at 12:01 a.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open on October 16, 2024. In connection with the Reverse Stock Split, every fifteen shares of the Company’s common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company’s common stock. No change will be made to the trading symbol for the Company’s shares of common stock, “MGRX”, in connection with the reverse split.

The Reverse Stock Split is part of the Company’s plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.

The Reverse Stock Split was approved by the Company’s stockholders at the Company's Special Meeting of Stockholders held on March 25, 2024 (the “Special Meeting”) to be effected in the Board’s discretion within approved parameters. Following the Special Meeting, the final ratio was approved by the Company’s Board.

The Reverse Stock Split will reduce the number of shares of the Company's outstanding common stock from approximately 35.5 million shares (as of the date of this press release) to approximately 2.4 million shares, subject to adjustment for rounding, as discussed below and potential additional issuances through the effective date of the Reverse Stock Split.

The reverse split will affect all issued and outstanding shares of common stock. All outstanding options and other securities entitling their holders to purchase or otherwise receive shares of common stock will be adjusted as a result of the reverse split, as required by the terms of each security, and in certain cases, subject to reset rights. The number of shares available to be awarded under the Company’s equity incentive plan will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 par value per share. The reverse split will not change the authorized number of shares of common stock or preferred stock. No fractional shares will be issued in connection with the reverse split, and stockholders who would otherwise be entitled to receive a fractional share will instead receive one whole share of common stock in lieu of such fractional share.

Additional information regarding the reverse stock split is available in the Company’s definitive proxy statement originally filed with the U.S. Securities and Exchange Commission (SEC) on March 1, 2024 and a Current Report on Form 8-K which the Company filed today with the SEC.

About MangoRx

MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, our ability to maintain the listing of our common stock on Nasdaq; our ability to meet Nasdaq’s minimum bid price requirement and other continued listing requirements of Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow MangoRx on social media:
https://www.instagram.com/mango.rx
https://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial

FOR INVESTOR RELATIONS

Mangoceuticals Investor Relations
Email: investors@mangorx.com

FAQ

What is the reverse stock split ratio announced by Mangoceuticals (MGRX)?

Mangoceuticals (MGRX) announced a 1-for-15 reverse stock split, effective October 16, 2024.

Why is Mangoceuticals (MGRX) implementing a reverse stock split?

MGRX is implementing the reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share and maintain its listing on the Nasdaq Capital Market.

How will the reverse split affect Mangoceuticals (MGRX) outstanding shares?

The reverse split will reduce MGRX's outstanding common stock from approximately 35.5 million shares to 2.4 million shares, subject to adjustments for rounding and potential additional issuances.

When will Mangoceuticals (MGRX) shares begin trading on a split-adjusted basis?

MGRX shares are expected to begin trading on the Nasdaq Capital Market on a split-adjusted basis at market open on October 16, 2024.